@Article{,
AUTHOR = {Fred Saad, Abdulhadi Al Dejmah, Paul Perrotte, Michael McCormack, François Bénard, Luc Valiquette, Pierre I. Karakiewicz},
TITLE = {Therapeutic approach to hormone-refractory prostate cancer},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {13},
YEAR = {2006},
NUMBER = {Suppl.2},
PAGES = {52--56},
URL = {http://www.techscience.com/CJU/v13nSuppl.2/63355},
ISSN = {1488-5581},
ABSTRACT = {Over 60 years ago, Huggins and Hodges discovered
androgen deprivation as an effective first-line therapy for
metastatic prostate cancer. This leads to significant cancer
control but in almost all men prostate cancer ultimately
progresses to a hormone-refractory (HRPC) state resulting
in significant morbidity and eventual death. In 2004, two
landmark studies using docetaxel based chemotherapy
demonstrated, for the first time, a survival advantage in
HRPC. This has set a new standard of care for this disease.
In addition, treatment with the bisphosphonate zoledronic
acid has been shown to significantly reduce bone
complications in metastatic HRPC. Building on these
advances, several new docetaxel/zoledronic acid based
combinations as well as new targeted therapies are under
development. Introducing these effective therapies earlier
in high risk patients is also under investigation to further
improve outcomes.},
DOI = {}
}